|

Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

RECRUITINGPhase 4Sponsored by Wei Zhao
Actively Recruiting
PhasePhase 4
SponsorWei Zhao
Started2016-01-31
Est. completion2025-12-31
Eligibility
Age1 Day – 18 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT03844360

Summary

The investigators' purpose was to assess the feasibility of dosage individualization of the commonly used antineoplastic drugs and anti-infective drugs in children with hematoplastic disease.

Eligibility

Age: 1 Day – 18 YearsHealthy volunteers accepted
Inclusion Criteria:

* Patients must be diagnosed with hematological neoplasms
* Antineoplastic drugs or anti-infective drugs used as part of regular treatment

Exclusion Criteria:

* expected survival time less than the treatment cycle;
* patients with other factors that researcher considers unsuitable for inclusion.

Conditions2

CancerHematological Neoplasms

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.